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OSA is almost universal in obese individuals who have 
a body mass index over 40 and a neck circumference of 
17 inches or more, but up to 30% of individuals with 
a BMI less than 30 have OSA.
from the Federal Air Surgeon’s 
PERSPECTIVE...
by Fred Tilton, MD
Untreated obstructive sleep apnea is a 
disqualifying condition for airmen and air 
traffic control specialists.
New Obstructive Sleep Apnea 
Policy
i 
hope you all had a happy and really scary Halloween, and 
that you will have a wonderful Thanksgiving. The purpose 
of this editorial is to alert you to a policy that we will be 
releasing shortly on obstructive sleep apnea (OSA). OSA is 
almost universal in obese individuals who have a Body Mass 
Index (BMI) over 40 and a neck circumference of 17 inches 
or more, but up to 30% of individuals with a BMI less than 
30 have OSA. 
OSA inhibits restorative sleep, and it has significant safety 
implications because it can cause excessive daytime sleepiness, 
cognitive impairment, cardiac dysrhythmias, sudden cardiac 
death, personality disturbances, and hypertension, to cite just 
a few. Untreated OSA is a disqualifying condition for airmen 
and air traffic control specialists (ATCSs), and it is a concern 
for the other modes of the Department of Transportation. It 
has also been a hot issue at the National Transportation Safety 
Board for several years. 
Dr. Nick Lomangino has been working on this policy for 
quite a while, and I think he has developed an outstanding 
product. We have purposely moved slowly because we wanted to 
give everyone an opportunity to learn about some of the issues 
before we added major changes to the medical certification 
process. We began by publishing educational OSA pamphlets, 
talking about the issues at flying safety meetings, and adding 
an OSA session to the curriculum of aviation medical examiner 
(AME) seminars.
The next step will be to require AMEs to calculate the BMI 
for every examinee (both airman and ATCS) by using a for-
mula that is located in the examination techniques section of 
the AME Guide and to record the results in Block 60 of FAA 
Form 8500-8. Airman applicants with a BMI of 40 or more 
will have to be evaluated by a physician who is a board certified 
sleep specialist, and anyone who is diagnosed with OSA will 
have to be treated before they can be medically certificated. 
Once we have appropriately dealt with every airman examinee 
who has a BMI of 40 or greater, we will gradually expand the 
testing pool by going to lower BMI measurements until we 
have identified and assured treatment for every airman with 
OSA. Note: We plan to implement the same assessment and 
treatment protocol for ATCSs, but we have to finalize some 
logistical details before we can proceed. 
While this policy focuses on obstructive sleep apnea, you as 
AMEs must also be on the alert for other sleep-related disor-
ders such as insomnia, parasomnias, or restless leg syndrome; 
or other physical anomalies such as a retrograde mandible, a 
large tongue or large tonsils, or neuromuscular or connective 
tissue disorders, because they could also be signs of problems 
that could interfere with restorative sleep.
I hope this editorial is of some use to you. I excluded a lot 
of detail because my intent was only to announce the new 
policy. The complete directions will be fully explained in the 
AME Guide. 
Remember, you, as aviation medical examiners, are 
our front line, and your daily interaction with pilots and 
controllers has an enormous impact on the safety of the 
national airspace. Thank you so much for what you do for 
the Federal Aviation Administration, the flying public, and 
the individuals you examine.
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Aviation Medical Examiner 
Information Links
AME Guide 
www.faa.gov/go/ameguide
AME Training Information 
www.faa.gov/go/ametraining
AMCS Online Support 
www.faa.gov/go/amcssupport
Regional Flight Surgeon Contacts 
www.faa.gov/go/rfs
Pilot Safety Brochures 
www.faa.gov/go/pilotsafetybrochures
Multimedia Aviation Medical Examiner 
Refresher Course (MAMERC):
www.faa.gov/go/ametraining
Medical Certification Information 
www.faa.gov/go/ame/
MedXPress Login & Help  
https://medxpress.faa.gov
MedXPress Video Page 
www.faa.gov/tv/?mediaId=554
FASMB Archives 
www.faa.gov/go/fasmb
CAMI Library Services 
www.faa.gov/go/aeromedlibrary
Airman Education Programs & Aerospace Physiology
www.faa.gov/pilots/training/airman_education/aerospace_physiology/
Dr. Berry Receives OneDOT Award 
By Kelly Vick
Regional Flight Sur-
geon  Daniel K. Berry, 
of the Central Region, 
received the Department of 
Transportation’s OneDOT 
Award as Manager of the 
Year for the Central Region. 
“Dr. Berry has changed 
the climate in the  Aero-
space Medicine Office 
in the Central Region,” 
said Central Region Ad-
ministrator  Joe Miniace. 
“He was selected for his 
leadership and success in 
managing people and programs. He managed a remarkable 
turnaround in the region by reestablishing relationships with 
other FAA Lines of Business and with the medical examiners 
in the field.” 
Dr. Berry’s leadership in managing the Aviation Medical 
Examiner (AME) Program resulted in the Central Region 
completing 154 of 170 AME site inspections in FY13. The 
region is on schedule to complete the remainder of the visits 
by the end of the year. 
Dr. Berry collaborated with headquarters to develop a new 
sleep apnea policy for airmen and air traffic controllers. He rec-
ommended changes that were incorporated into the final policy 
that will soon be released to all FAA Regional Flight Surgeons. 
Another major revision he is working on is to the Airman Analyst 
Program Manual to incorporate new conditions under which 
AMEs may certify pilots. This represents the most significant 
change to the way the FAA administers airman medical certi-
fication in 10 years. 
His focus on high quality and individualized service has 
resulted in a dramatic reduction in airmen complaint letters and 
congressional inquiries regarding airman medical certificates. 
His outreach through Congressional listening sessions, lectures 
to university aviation programs, pilot meetings and conferences, 
and interaction with individual aviators has contributed to 
improved customer satisfaction and understanding of the FAA 
medical process. 
Q
Ms. Vick is the editor of the AVS Flyer in the FAA Office of Aviation Safety.
Dr. Daniel Berry (r) receives One-
DOT award from Central Region 
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OAM Physicians On Call, Part 3
An Extension of Conditions AMEs Can Issue (CACI) 
By Richard Carter, DO, MPH
Recap—In Part 1 of this series, we asked you to help us 
minimize our backlog of deferred examinations by issuing cer-
tificates when you can. In Part 2, we provided guidance for 
more complex cases: dispositions that would require a verbal 
authorization to issue. The case examples described circum-
stances that were straight forward enough, with adequate 
medical reports in hand, to allow you to issue with a ver-
bal authorization from the Aerospace Medical Certification 
Division (AMCD) or your Regional Flight Surgeon (RFS). 
I
n this paper, we circle back to the theme of Cases/conditions 
AME Can Issue (CACI) without a requirement to defer 
or call for verbal authorization. Part 1 provided a CACI 
list, and that list is again included with additional conditions 
and some revisions. New CACI guidelines do, indeed, involve 
more complex conditions, and we do need for you to collect 
information (medical reports) that will allow you to issue. 
Issue when you can. A phone call to the AMCD is not 
always required. The AME Guide provides CACI instructions, 
primarily in three sections of the Guide: Protocol, Dispositions, 
and Worksheets. 
The Protocol section of the AME Guide 
Disease Protocols 
lists some conditions allowable for you to initial issue (for 
example, a right BBB—in an otherwise healthy person 30 
years of age or younger should not require a CVE; or diabetes 
controlled by diet/exercise, in both cases, AME may issue with 
notes in box 60). Complications can occur, and we invite you 
to call about abnormal labs, ECGs, etc. ECGs are still required 
for Class 1, so we need those, even if you regular issue (see the 
10 Common ECG Issues, page 5). 
The Dispositions section of the AME Guide 
aerosPace MeDical DisPositions 
also lists conditions for which you can issue (e.g., prostate cancer, 
without evidence of extra-capsular disease). 
The AME Guide has recently added a worksheet section 
certification worksheets
that provides more conditions for which you can issue (e.g., 
glaucoma worksheet, hypertension worksheet). Worksheets are 
checklists, so you do not need to forward them to the AMCD, 
but we do need a specific statement placed in block 60 from the 
worksheet if all criteria were met. You must use the worksheet 
in conjunction with the disposition table for that condition. 
CACI up to date. So, what is new? Take a look at the 
Archives section of the AME Guide to find posted changes 
and dates of the changes 
archives anD MoDifications of the GuiDe for aviation MeDical exaMiners 
Example of Archives entry, “ …revise dispositions table for 
prostate, renal, and testicular carcinomas. Introduce renal 
cancer worksheet with certification criteria under which you 
can regular issue.” 
CACI is a longer list. (see CACI list  on page 6). Note, 
this is not a complete list of conditions that qualify for an 
Eligibility /CACI Letter, but a sample of typical questions/
conditions AMEs call about). The list includes many of the new 
changes in the AME Guide. The AME Guide has emphasized 
certain conditions, with the inclusion of worksheets. Current 
certification worksheets:
arthritis  asthMa
GlaucoMa  hePatitis c - chronic
hyPertension  hyPothyroiDisM
MiGraine anD chronic heaDache
Pre-Diabetes  renal cancer
The Guide still lists many medical conditions that are 
initially disqualifying. Protocols, disposition tables, and 
worksheets all provide instructions to allow you to issue 
under specified conditions. Worksheets, for example, do 
not represent a special class of conditions that are somehow 
different in disposition. Worksheets are just another source 
of instructions to the AME. Not all applicants will meet 
CACI criteria (protocol, disposition tables, worksheets) or 
AASI criteria.
Complicated situations. You can call the AMCD or your 
RFS for questions regarding complicated situations when the 
AME Guide does not allow you to directly issue. AMEs that are 
given an initial Verbal Authorization to issue must send in the 
medical reports. Please, do not mail, fax, or otherwise send in 
duplicates of the same reports. Simply put, you can issue cases 
that allow for CACI/Eligibility Letter, or Regular Issue, and in 
general, do not need to send in medical reports for conditions 
that do not require a time-limited certificate, unless requested 
by AMCD/RFS or a letter. 
Verbal authorization to issue. For uncomplicated cases 
that require a time limitation, you can call the AMCD number 
(405) 954-4821/option 6. Dedicated operators will route you to 
the medical officer on call. Please follow operator instructions. 
If we are not immediately available, we will try to call back the 
same day. We may also ask for an after-hours call-back number 
(usually your cell number), as we may return your call after 
normal working hours. The operators take calls from 0800 to 
1615 CST.
When you call, we will want you to discuss the detailed 
written reports from the airman’s clinical provider. We need 
a description of the medical condition, history, exam, tests, 
treatment plan, and prognosis. We also need your clinical 
description of how the airman is currently doing and if you 
have any concerns, since you actually see them in your clinic. 
Even if you are not a pilot, ask yourself: If I had to fly with 
this pilot, would I want to do it with this person in this condition? 
Conditions acceptable for a verbal authorization include stable 
central serous retinopathy and stable obstructive sleep apnea. 
The vast majority of cases are ultimately granted a medical 
certificate. This is a tribute to the hard work of AMEs tracking 
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10 Common ECG issues 
What to Do About Them When Performing 
Certification ECGs†
1.  If an airman has a heart rate less than 50, have the airman 
exercise in place and repeat the ECG. If the heart rate goes 
up above 50, send us both ECGs (in case this happens again 
down the road), and you can clear the airman.
2.  This also goes for a significant first degree AV block. Exercise 
the airman in place, and if the block becomes less, you may 
clear the airman.
3.  If an airman has a rate over 110 (sinus tachycardia) perhaps 
have the airman relax a bit and repeat the graph. If the rate 
drops below 110, send us the graph and clear the airman.
4.  Two or more premature ventricular contractions (PVCs) on 
an ECG require the applicant to have a maximal nuclear 
stress test. If this has been previously worked up, you do 
not need to provide a new evaluation. Premature atrial 
contractions (PACs) if not symptomatic, do not require a 
workup. 
5.  If the airman demonstrates new onset of left or right bundle 
branch block see Bundle Branch Block Protocol.  
6.  An airman who has an incomplete RBBB pattern on previ-
ous electrocardiograms, and then demonstrates a complete 
RBBB, does not require an evaluation.
7.  An airman with a new onset of a complete left bundle branch 
block is to provide a cardiovascular evaluation and a phar-
macologic nuclear stress test. This is one of the conditions 
where we will accept a pharmacologic stress test. Airmen 
with a LBBB demonstrate what appears to be an area of 
ischemia in the septum, and the pharmacologic stress test 
helps better determine if there is actual ischemia.
8.  An airman with left anterior or posterior hemiblock must 
demonstrate an absence of coronary artery disease, so a 
maximal nuclear stress test is required.
9.  Limb lead III is the most variable lead. This lead sometimes 
is affected by respiration, which can falsely indicate that 
the airman had a previous inferior infarction. So if you 
have a small R-wave with a deep S-wave in that lead, and 
even perhaps in lead aVF, you need to perform an ECG in 
inspiration and again in expiration. If the S-wave disappears 
and you get a larger R-wave, you can clear the airman—but 
don’t forget to provide us all these graphs.
10. An airman who has ST- and T-wave changes that suggest 
ischemia or left ventricular hypertrophy requires an eval-
uation if one has not been previously performed for this 
reason. 
Q
†Important: Please provide applicant’s correctly spelled name and 
two other identification criteria: DOB, SSN or psuedo SSN, PI, 
or MID no.
This article was previously published in the Bulletin.
down reports of tests and procedures, and consulting with the 
airman’s physicians to provide a satisfactory narrative of the 
current medical status and prognosis. 
CACI case examples that may or may not require you to 
call AMCD
Example 1 (worksheet). Third-class, thyroid cancer, 6 yrs. 
ago, new, initial airman application, stable. Hypothyroid condition 
on Synthroid, with favorable reports (surgical report, hospital 
records, and updated current status), all with good prognosis. AME 
did call. Advised AME to issue regular certificate. AMCD will 
send the airman an Eligibility/ with warning only, for the history of 
thyroid cancer, and additional comment, “at the time of your next 
FAA physical exam, you will be required to bring current reports 
and/or test results to your follow-up with your AME regarding 
your history of hypothyroidism.” This is a CACI letter. AASI is 
not required for the hypothyroid condition/medication, and we 
included a warning for the past thyroid cancer and surgery. So, 
you may perform subsequent exams and issue a certificate if the 
results and test reports continue to be favorable. 
Example 2 (worksheet). Second-class airman, new diagnosis 
of increased ocular pressure, airman provided a summary report 
from the ophthalmologist, medication (Xalatan, prostaglandin 
analog) needed, no “true” glaucoma, as the visual fields are normal. 
The CACI worksheet allows you to issue if all worksheet checklist 
parameters are met. No reports need to be sent to AMCD. We do 
need specific comments in block 60, “Airman meets certification 
criteria for glaucoma.” You may add additional information such 
as “favorable ophthalmologist report, medication (Xalatan), well 
tolerated, visual fields are normal.” You do not need to call prior 
to transmitting the new exam. You can then issue a regular, 
non-time-limited certificate (if no other conditions) and transmit 
the exam. 
Example 3 (Aerospace Medical Dispositions table). Third-
class airman, history of new diagnosis, prostate cancer, status 
post-surgery, recovered without sequelae, PSAs are zero. The 
cancer was confined to the gland…good prognosis. You go to 
the AME Guide Disposition table (no worksheet) for prostate 
cancer, review a current status report, all pertinent medical reports 
(staging, PSA, metastatic workup, and operative report), and note 
prostate cancer confined to gland. You can regular issue, and it is 
not necessary to call prior to transmitting the new exam. You can 
then issue the regular, non-time-limited certificate (if no other 
conditions), put note in box 60 showing “PC stable, no mets,” 
and transmit the exam. 
Team effort. We really need your  help  to limit unnecessary 
deferrals. Many complex medical conditions do eventually get 
a waiver (special issuance or SODA), and we will help you with 
the certification process. Together, we can expedite the timely 
medical certification of pilots. 
Next time. We will discuss more conditions and the specific 
information you should help your airman collect to expedite a 
medical certification decision. 
Q
Dr. Carter, an AMCD Medical Review Officer, thanks Dr. Judy Frazier 
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  » Arthritis 
—If only PRN NSAIDS and under good control: Issue (no 
worksheet required)
—If on acceptable medications (NSAIDS, methotrexate, 
hydrochloroquine (Plaquenil) – requires eye report): see   
disposition table and worksheet
  » Asthma
—See disposition table and worksheet
—If only on PRN 1-2 days per week and good control: Issue 
(no worksheet required)
—If on daily albuterol or inhaled steroids: see worksheet
  » Benign Prostatic Hypertrophy (BPH) 
—On no medication—Issue 
—On an acceptable medication (note AMCD does require 
comment in block 60 that medications are well tolerated) 
—Avodart (dutasteride), Uroxatral/alfuzosin), Flomax 
(tamsulosin) 
—Rapaflo (silodosin): up to 8 mg a day is acceptable—requires 
2-week observation period. 
—If used for other than BPH, Special Issuance
—Current policy change identifies the following medications 
as NOT acceptable (these will need to be deferred): Detrol 
(tolterodine), Ditropan (oxybutynin), Enablex (darifenacin), 
Vesicare (solifenacin), Sanctura (trospium)
  » Cholelithiasis, asymptomatic
– Issue
  » Diabetes, diet controlled
—See disposition table 
  » Eardrum Perforation 
—Resolved: Issue
  » Erectile Dysfunction medications 
—AMCD requires comment in block 60 that medications 
are well tolerated:
• Viagra (sildenafil citrate): 6 hours no fly
• Levitra (vardenafil): 36 hours no fly
• Cialis (tadalafil): 36 hours no fly, daily form is DQ
  » Esophoria/Exophoria 
—No adverse complications, no diplopia (see Item 54 of the 
AME Guide)
  » Glaucoma 
—See worksheet (requires normal visual fields)
  » Gout on medication, examples 
—AMCD requires comment in block 60 that medications 
are well tolerated):
• Currently acceptable: Colcrys (colchicine), Uloric (febux-
ostat), Zyloprim (allopurinol), Benemid (probenecid)
  » GU cancers 
— > 5 years ago, no history of metastatic disease, stable:   
see disposition table 
  » Hepatitis C
—See worksheet
  » Hypertension 
—See worksheet
  » Hypothyroidism 
—See worksheet
  » Intraocular Lens, Multifocal 
—See Protocol for Binocular Multifocal and Accommodating Devices
  » Kidney Stone
—Resolved, or nephrocalcinosis (fine granular mottling in 
the parenchyma) with favorable report: Issue 
  » LASIK 
—Less than two years – we need completed Form 8500-7. If 
favorable — 0151: Issue
—more than two years – comment no adverse complications 
(AME comments block 60): Issue
  » Melanoma 
—(< .75 mm) complete excision, favorable report: Issue
  » Migraine and Chronic Headache 
—See worksheet
  » Motion Sickness 
—Resolved: Issue
  » Musculoskeletal injury
—If condition resolved or does not cause functional impair-
ment, we need description of current function in block 60
  » Myringotomy 
—Resolved: Issue
  » Nephrectomy (non-cancer)
—Full recovery: Issue
  » Nephritis
—Acute episode, s/p 3 months, resolved with favorable 
reports, Issue
  » Overactive Bladder 
—Myrbetriq (mirabegron) is allowed after 2 weeks if no 
side effects 
  » Pneumothorax, Traumatic
—s/p 3 months, resolved, with favorable reports: Issue 
  » Polycystic Kidney Disease
—Normal renal function and no HTN: Issue
  » Pre-Diabetes 
—(Metabolic syndrome): see worksheet
  » Prostate Cancer 
—No evidence of extra-capsular disease: Issue 
  » Renal Cancer 
—See worksheet 
  » Situational Stress (bereavement), or adjustment disorder 
—If stable, resolved, no associated disturbance of thought, no 
recurrent episodes, and psychotropic medication(s) used for less 
than 6 months, and discontinued for at least 3 month: Issue
  » Testicular Cancer
—Treatment complete without sequela: Issue 
Q
Conditions AMEs Can Issue (CACI)
A-Z List of All Conditions and Medications That Apply
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DUI Reporting Requirements
Debunking the Myths 
By Lesha Sloan-Thompson
influence/while impaired, etc.; (2) any arrest and/or conviction 
and/or administrative action that resulted in the denial, sus-
pension, cancellation, or revocation of your driving privileges 
(note: this is not limited to alcohol-related events); and any 
attendance at an educational or rehabilitation program. 
We hope an airman will openly discuss details related to 
these events, along with any other information asked on the 
form, with his aviation medical examiner. However, as an 
AME, you may wish to discuss any “yes” response to Question 
18v. with the applicant, as well as asking them if they have 
provided a written report to the Security Division regarding 
any administrative action and/or conviction associated with 
the alcohol-related motor vehicle incident. 
Please note, if an airman answers “yes” and references 
“previously reported,” they will not be in compliance with the 
regulations unless they have detailed the alcohol incident on 
the first application following the alcohol-related motor vehicle 
incident.
To address other questions you may have about DUI re-
porting requirements, please refer to the DUI/DWI Program 
website at
www.faa.gov/go/duidwi
or call the program office at (405) 954-4848 to speak with an 
investigator. All questions you may have concerning the issu-
ance of a medical certificate should be directed to either your 
Regional Flight Surgeon or by contacting the Civil Aerospace 
Medical Institute in Oklahoma City (405) 954-7675.
Remember, you are our greatest asset in being able to 
educate your peers, applicants, and your surrounding aviation 
community of these important requirements.
Q
Lesha Sloan-Thompson manages the Regulatory Investigations Branch, 
AMC-760.
CME Credits a Bonus to Some
By Janet Wright
Dr. Richard Carter, of the Civil Aerospace Medical In-
stitute, recently visited with a representative of the DUI/DWI 
Program in regards to the dual reporting requirements for 
alcohol- and drug-related motor vehicle actions. Most airmen 
are aware that such actions must be reported on their applica-
tion for Airman Medical, but there continues to be confusion 
regarding the 60-day reporting requirement defined by 14 
CFR 61.15(c)(1)(2)(3), in addition to what specific actions are 
reportable on an Application for Medical Certificate, FAA 
Form 8500-8. Discussion centered on the confusion that even 
the most experienced pilot can have of the different reporting 
requirements, so we hope this article helps to debunk the myths 
and provide you with a greater understanding of the reporting 
requirements. 
An airman has two separate reporting requirements involv-
ing alcohol-related motor vehicle actions; one report per Title 14 
of the Code of Federal Regulations (CFR) 61.15(e) and one to 
you, the aviation medical examiner (AME), via the Application 
for Airman Medical, FAA Form 8500-8. To help clarify, the 
reporting requirements of both are summarized below:
What is reportable under 14 CFR 61.15(e)? Alcohol-related 
motor vehicle actions such as suspensions, revocations (here-
after referred to as administrative actions), and convictions for 
offense such as driving while under the influence, driving while 
impaired, operating under the influence, etc. Please note the 
suspension/revocation AND convictions are separate, report-
able actions under this regulation—even though they may be 
related to the same incident. These reports must be received 
by the DUI/DWI office within 60 days of the alcohol-related 
motor vehicle action.
What is reportable on your application for Airman Medical, 
FAA Form 8500-8, specifically question 18v? (1) Any arrest and/
or conviction involving driving while intoxicated/under the 
Hello aviation medical examiners! You probably know 
that your Basic and Refresher training seminars are awarded 
Continuing Medical Education credits.† What you may not 
know is that if your specialty is Aerospace Medicine, those 
same hours may also meet your Maintenance of Certification 
(MOC) requirement. 
After each seminar you attend, you will receive a certificate 
showing that we are an accredited entity, how many hours you 
participated, and the name and date of the seminar. You should 
submit this to the board from which you are requesting MOC 
credit. You may or may not be asked to send the seminar agenda, 
so hang on to it. That’s it; pretty simple!
If you have questions feel free to call or email me 
405-954-4803 
janet.e.wright@faa.gov
Q
Ms. Wright is the Aerospace Medical Education Division Team Lead 
for AME Education.
†The Civil Aerospace Medical Institute is accredited by the Accredita-
tion Council for Continuing Medical Education to provide continuing 
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Vertebral Artery Dissection in an 
Airline Pilot
Case Report, by Dean M. Olson, MD, MS
Although rare in the general population, a pilot experienc-
ing a vertebral artery dissection in flight would have signifi-
cant and deleterious consequences. Vertigo, ataxia, dysarthria, 
and diplopia would be catastrophic in the context of airline 
transport. In this neurologic emergency, the lives of the pilot, 
the air crew, and the passengers would be at risk.
History
a  
36-year-old male airline pilot experienced acute onset 
of aching pain in his right occipital region while sitting 
on a couch. His neck pain was followed quickly by numbness 
on the right side of his face and in both extremities especially 
on his right side. The pilot denied any loss of function but did 
experience difficulty ambulating when he got up to go to the 
bathroom. He felt as though he was listing to the right because 
of a lack of sensation of the floor in his right leg. He was worried 
that he “might be having a stroke” and subsequently called for 
an ambulance. 
By the time the ambulance arrived, his symptoms had 
resolved. Throughout his experience, he denied any chest pain, 
heart palpitations, shortness of breath, or focal weakness. The 
pilot did relay to the emergency physician that the day before 
his symptoms occurred he did take part in a judo class and felt 
he was “beaten up” as he had multiple bruises over his body. 
He denied any specific injury to his head or his neck during 
his workout.
His medical history was negative. His family history was 
significant only for migraine headaches suffered by his mother. 
Socially, the pilot was a non-smoker, and he denied any allergies.
In the emergency room, his vital signs, including oxygen 
saturation, were normal except for a blood pressure of 140/98. 
His exam performed by the ER physician was normal and 
the patient stated that he was feeling normal at that time. An 
ECG demonstrated a normal sinus rhythm without any signs 
of ischemia; a CT scan of the brain was negative.
He was admitted to the hospital neurologic service and 
underwent carotid duplex imaging, which demonstrated an 
absence of normal flow in the right vertebral artery, suggestive 
of thrombosis or vertebral artery dissection. An MRA demon-
strated absences of flow in the right vertebral artery without 
any intracranial abnormalities. The pilot was then started on 
anticoagulation therapy.
The pilot was discharged and remained on warfarin for a 
six-month treatment period and subsequently was treated with 
aspirin 81 mg daily. Nine months after his original symptoms, 
Etiology of VAD
Vertebral artery dissection (VAD) is a rare condition. The 
combined incidence with carotid artery dissection is 2.6 per 
100,000 and has a mortality of 10% (3). It generally occurs in 
younger patients, with a median age of 40 years (1) and has a 
female to male ratio of 3:1 (3). The root lesion is a hematoma 
in the vessel wall or an intimal flap that develops at the inner 
lumen of the vessel. It may occur spontaneously or may be 
associated with trauma involving sudden extension or rotation 
of the neck. It has occurred following high-energy events such 
as high-velocity motor vehicle accidents and diving injuries 
but has also occurred following less energetic events such as 
chiropractic neck manipulation, sneezing, and coughing. It, as 
well, has been documented in mixed martial arts (4).
There are four segments of the vertebral artery (3):
1.  Segment I begins at the subclavian artery and ends at the 
transverse foramina of C5 or C6.
2. Segment II is the section of artery from the transverse fo-
ramina of C5/C6 to C2.
3. Segment III is surrounded by muscle, nerve, and the atlan-
to-occipital membrane and is tortuous. It starts at C2 and 
travels around the posterior arch of C1, then between C1 and 
the occiput and ends at the foramen magnum.
4. Segment IV begins at the foramen magnum, pierces the dura 
matter, and travels laterally around the brainstem where the 
two vertebral arteries meet anteriorly, forming the basilar 
artery near the pons-medulla junction. 
Hematoma and intimal flaps may form in any segment of the 
vertebral artery. Lesions of various sizes may result in minimal 
narrowing of the vessel, with minimal symptoms or result in 
complete occlusion with significant impairment. Intimal disrup-
tion and altered blood flow dynamics result in a thrombogenic 
environment. Clot formation with subsequent emboli may cause 
transient ischemia or significant infarct. Of special note, sponta-
neous VAD usually occurs in segment III and may extend into 
segment IV, causing intracranial pathology. A subadventitial 
dissection that occurs in segment IV may rupture and cause 
subarachnoid hemorrhage, which must be ruled out prior to 
initiating anticoagulation therapy. Patients suffering VAD typically 
present with occipital and/or neck pain, headache, vertigo, and 
may have symptoms of brainstem TIA or stroke. In these cases, 
urgent diagnostic imaging is required, as well as a referral to 
neurosurgery. 
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the pilot underwent a second MRA, which demonstrated a 
“diminutive” right vertebral artery that was filling in a retro-
grade fashion and was felt to be congenitally small, based on 
lumen size. During this period, he remained symptom-free.
Aeromedical Concerns
In the flight environment, the acute onset of vertebral artery 
dissection (VAD) would have a significant impact on a pilot’s 
ability to safely operate the aircraft. It has been well established 
in aerospace physiology that vertigo can be disabling for a pilot 
leading to an inability to maintain proper aircraft attitude. 
Further complications of VAD, such as dysarthria, diplopia, 
transient ischemic attack, and stoke— even if transient—could 
result in a pilot’s complete inability to operate the aircraft and 
would have disastrous results. The pilot’s deficiencies could 
range from minimal functional deficit to full incapacitation, 
resulting in being unable to operate aircraft control surfaces, 
difficulty seeing the flight instruments, and an inability to 
operate avionics or speak to air traffic control. A pilot who ex-
periences VAD while outside the flying environment and who 
suffers continued symptoms should be grounded for similar 
safety concerns. 
Outcome
Although not specifically listed, vertebral artery dissection 
falls under the category of cerebrovascular disease in the online 
Guide for Aviation Medical Examiners (2). According to this 
section, a history or the presence of any neurological condition 
or disease that potentially may incapacitate an individual should 
be regarded as initially disqualifying. A medical certificate must 
not be issued, and the applicant’s case should be deferred to 
the Aerospace Medical Certification Division or the Regional 
Flight Surgeon. The airman must submit all pertinent medical 
records, including neurologic reports, imaging studies, and 
medication dosages and side effects. 
The pilot complied with all requests for documentation. The 
policy for such an event is that the airman be grounded for 12 
months. This airman was over 12 months when he presented for 
consideration for a medical certificate. Given that he underwent 
6 months of anticoagulation therapy on warfarin and remained 
symptom-free, the pilot was issued a Class-1 Special Issuance 
with a return to full flight status. He was given a time-limited 
authorization of 12 months, requiring an annual status report 
from his physicians and an MRA of the brain at that time. 
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Thiazide-Induced Hyponatremia 
Associated With Acute Mental 
Status Changes
Case Report, by Susan R. E. Fondy, MD, MPH
Thiazide diuretics are frequently used to control 
hypertension in airmen. A small percentage of individuals 
treated with thiazides will develop thiazide-induced 
hyponatremia, a side effect that can cause generalized, 
musculoskeletal, and neurologic symptoms ranging from mild 
to profound. Familiarization with these side effects will allow 
the aviation medical examiner to recognize, avoid, and treat 
this condition in airmen.
Case Presentation
a    
64-year-old commercial airline captain with ap-
proximately 16,000 hours of flight time presents for 
clearance following an episode of acute mental status change. 
The airman has a history of obstructive sleep apnea (OSA) and 
recently diagnosed hypertension. He is presently on 25 mg 
hydrochlorothiazide once daily and uses a nasal continuous 
positive airway pressure device nightly.
On the day in question, the airman failed to arrive at the 
airport for a scheduled flight. After calling his hotel room and 
receiving no answer, the first officer entered his room with a 
hotel staff member and physically shook the captain awake. At 
the airfield, the first officer reported to the aircraft while the 
captain used the computer for preflight checks. The captain was 
noted to have difficulty with this very familiar task, requiring 
the assistance of airfield staff to log on and obtain the required 
information. He complained of being very tired and stated that 
he felt like he could sleep “all day.” He was observed by the 
airfield staff to have difficulty with coordination and balance 
while walking to the aircraft, staggering on several occasions, 
and stumbling on the stairs. He behaved in a disengaged manner 
once on board the aircraft and failed to begin his portion of 
the preflight checklist. The airfield manager was sufficiently 
concerned by this observed behavior that, after talking with 
the captain and the crew, he grounded the flight. Evaluation 
by a local police officer was significant for poor ocular pursuit 
though not true horizontal gaze nystagmus, and was negative 
for the smell of alcohol on the captain.
Following the grounding of the flight, the first officer 
brought the captain to a local hospital emergency department, 
where he was noted to have poor cognition, memory, and was 
ataxic. He was unable to remember many of the events that 
had just transpired. His serum sodium was found to be 117. An 
MRI of his brain showed questionable mild cerebral edema. 
Initially, he had limited response to attempts to increase his serum 
Etiology  
Thiazide diuretics have been used to control blood pressure 
for over 50 years.1 They are used alone or in conjunction with 
other agents and have been remarkably successful in reduc-
ing hypertension-related morbidity and mortality.2 They are 
known, however, to cause electrolyte disturbances in a certain 
percentage of patients. 
Thiazide diuretics function at the level of the distal convoluted 
tubule in the kidney by inhibiting the sodium-chloride symporter. 
This increases the sodium load in the urine and consequently, 
by osmosis, increases water excretion. Because the function 
of thiazide diuretics is on the distal tubule, they normally do 
not significantly affect the overall sodium content of the body; 
however, a certain percentage of the population will have an 
unusually large sodium loss. The increase in sodium con-
centration delivered to the distal portion of the distal tubule 
promotes potassium secretion into the urine. This potassium 
secretion exacerbates the sodium loss by promoting a net flow 
of sodium into the intracellular space, increasing the likelihood 
of hyponatremia.3
Hyponatremia as a consequence of thiazide diuretic use is 
well described in the literature. While it is not exceptionally 
common, a large Chinese study found that it occurred within 
eight weeks of the initiation of thiazide diuretics in 5.9% of their 
study population.4 These incidences were positively associated 
with male gender, older age, and use of thiazide as opposed to 
other diuretics in the 2009 study by Jiang et al. 4 Interestingly, 
however, Assen and Mudde note the incidence of hyponatremia 
to be more prevalent in older females with low body weight in 
their 1999 case report.3 
Hyponatremia can cause severe neurocognitive deficits, with the 
most concerning symptom being cerebral edema.5 As the brain 
swells, the patient can experience nausea, vomiting, confusion, 
lethargy, fatigue, decreased appetite, restlessness, irritability, 
seizures, alteration in consciousness, and coma.5 The more 
rapid the onset of the hyponatremia, the less time the brain will 
have to undergo adaptive electrolyte loss to prevent cerebral 
edema; therefore, acute onset hyponatremia is more likely to 
lead to neurologic damage and death. Even modest levels of 
hyponatremia in the range of 126–134, once thought to be be-
nign, have been shown to cause ataxia, cognitive impairment, 
increased falls, fractures, and inpatient mortality.6 Of patients 
with severe hypotonic hyponatremia, 41% can be attributed to 
thiazide and indapamide diuretics.7 In addition to cerebral edema 
and its associated symptoms, hyponatremia can also cause 
muscle spasms, cramps, and weakness due to inefficiency of 
the sodium-potassium pumps within the muscle.
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sodium level. The following day, his hydrochlorothiazide was 
discontinued, and he was changed to an antihypertensive from 
a non-thiazide class. His sodium improved and then normalized 
after the medication change. Polysomnogram and maintenance 
of wakefulness test were remarkable for well-treated OSA. EEG 
and 24-hour EEG were normal. Alcohol level was negative. 
Aeromedical Concerns
The primary aeromedical concern with thiazide-induced 
hyponatremia is neurologic alteration, which can range from 
very subtle findings to the profound impairment that was seen 
in this case. As with any new medication, airmen initiating the 
use of thiazide diuretics should be monitored closely, especially 
in the early stages of treatment. Frequent electrolyte studies 
will allow the early diagnosis of hyponatremia, and such lab-
oratory evaluations should be completed after initiating the 
medication and prior to the airman being cleared to return to 
flight. Electrolyte monitoring is critical because the neurologic 
abnormalities that occur in the mildly hyponatremic range can 
be more subtle, and at times, subtle enough to be diagnosed 
only by specific neurological testing. While it is more common 
for hyponatremia to occur soon after starting thiazides, delayed 
hyponatremia can occur after months or even years, so mon-
itoring should be continued as long as the airman continues 
to take thiazides.
Additionally, the aeromedical examiner must be aware, 
especially after an acute episode such as this one, that persistent 
neurological deficits can occur. These can be a consequence of 
cerebral edema, demyelinization, or overly aggressive correction 
of profound hyponatremia. A complete work up, including MRI, 
EEG, neurologic evaluation, and neuropsychiatric evaluation 
must be completed prior to restoring flight status. If these are 
all normal or within acceptable aeromedical tolerance, the 
airman may receive an eligibility letter or may be given special 
issuance if follow-up is needed.
Outcome
The airman in the case was admitted to the hospital 
where he underwent extensive testing to ensure that there 
were no other causes for his hyponatremia. He was switched 
to another antihypertensive medication, and his sodium levels 
and neurological function improved. A repeat MRI, following 
the medication change and normalization of serum electrolytes, 
was normal. After hospital discharge, he was observed on his 
new medication for a period of three months and was found to 
have good blood pressure control. A neurocognitive examination 
showed that he had returned to full normal function, so he was 
cleared to return to flight.
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Primary Sclerosing Cholangitis
Case Report, by David B. Trant, MD, MPH 
Primary sclerosing cholangitis (PSC) is a chronic, pro-
gressive disease that is characterized by inflammation, fibrosis 
and stricturing of the intra- and extrahepatic bile ducts. It is 
likely immune-mediated in etiology, leads to progressive cir-
rhosis and liver decompensation in the majority of patients, 
and is one of the most common chronic liver disorders leading 
to orthotopic liver transplantation. A case report of an Airline 
Transport Pilot with a history of PSC is presented, along with 
a brief review of the disease and its aeromedical concerns. 
History 
A 
59-year-old male Airline Transport Pilot with over 
13,000 hours of flight time applied for consideration 
of renewal of a special issuance first-class medical certificate 
following liver transplantation 8 years previously due to end-
stage liver disease. His liver disease was secondary to primary 
sclerosing cholangitis (PSC) associated with ulcerative colitis. 
He had been diagnosed with PSC in 2001 when he was found 
to have abnormal liver tests and jaundice, and shortly thereafter 
he developed weight loss. As part of his evaluation, he under-
went colonoscopy. Pancolitis was noted at that time, and he was 
ultimately diagnosed with asymptomatic ulcerative colitis. He 
subsequently developed mild hepatic encephalopathy and a rise 
in his CA 19-9 titer (which is worrisome for cholangiocarcinoma 
in patients with PSC) and underwent liver transplantation. No 
hepatic cancer was found, and his encephalopathy and weight 
loss quickly resolved after surgery. 
The airman reported no symptoms at the time of his recent 
exam. Specifically, he denied any bleeding, abdominal pain, 
itching and swelling, shortness of breath, diarrhea, weight loss, or 
jaundice. His post-liver transplantation course was complicated 
by biliary strictures that were treated with dilation and stent 
placement approximately 5 years after surgery (3 years ago). He 
had not had any further symptoms of hepatic encephalopathy 
and was noted to be fully active and independent. Studies done 
during his most recent liver transplant follow-up visit (within 2 
months of presentation) showed no evidence of cirrhosis by CAT 
scan, but splenomegaly was noted. He underwent liver biopsy, 
which showed no evidence of rejection, but there was chronic 
hepatitis with mild portal inflammation and scattered focal 
bile duct damage consistent with recurrent primary sclerosing 
cholangitis. Colonoscopy performed 1 year ago showed no 
lesions, and pathology reports were unremarkable. Laboratory 
was remarkable for a normal bilirubin, platelets chronically 
diminished at 50k (attributed to hypersplenism), INR 1.1 (0.8-
1.3), alk phos 156 U/L (28-110), AST 61 U/L (7-40), ALT 40 
U/L (7-56), and GGTP 45 U/L (12-58).
His medications were mesalamine, tacrolimus, ursodiol, 
Vitamin K, allopurinol, and ranitidine. 
 
PrimAry SclEroSing cholAngitiS (PSc)
PSC is a chronic, progressive disease that is characterized by 
inflammation, fibrosis, and stricturing of medium and large intra-
hepatic and extrahepatic biliary ducts, leading to the formation 
of multiple bile duct strictures. The estimated incidence in the 
United States is 0.9 to 1.3 cases per 100,000 population, and 
there is a strong 70% male predominance of affected individuals. 
The average age at diagnosis is in the fourth decade, but age 
at presentation can range from 1 to 90 years (3). 
While the etiology of PSC is unknown, it is likely an immune- 
mediated progressive disorder that eventually develops into 
cirrhosis, portal hypertension and hepatic decompensation in 
the majority of patients (5). PSC often presents as an asymp-
tomatic elevation of liver enzymes, and only 50% of patients 
have abnormal physical findings (jaundice, hepatomegaly, 
splenomegaly). Symptoms, when present, include right upper 
quadrant abdominal pain, pruritus, jaundice, fatigue, weight loss, 
and fever (3). Inflammatory bowel disease (IBD) is a common 
associated finding, occurring in 60-80% of PSC patients. 
Ulcerative colitis is the most frequent type of IBD associated 
with PSC (1). 
The diagnosis of PSC is usually made by finding multifocal, 
diffusely distributed strictures with intervening segments of 
normal or dilated ducts, producing a beaded appearance on 
endoscopic retrograde cholangiopancreatography (ERCP) or 
magnetic resonance cholangiopancreatography (MRCP; 1,2).
Ursodeoxycholic acid (UDCA) has been shown in some studies 
to decrease the symptoms of PSC (especially pruritus) along 
with improving liver biochemistries in patients with PSC, but its 
overall impact on disease progression and prognosis has been 
inconclusive. High-dose ursodeoxycholic acid has recently been 
shown to increase the adverse events rate (6). Immunosuppres-
sive therapy has shown little benefit. The mainstay of treatment 
for patients with PSC who have advanced disease is liver trans-
plantation (9). Osteoporosis and fat-soluble vitamin deficiencies 
are associated with PSC, and appropriate replacement therapy 
is recommended. Calcium and Vitamin D supplementation are 
the primary drugs for treatment of osteopenia or osteoporosis. 
Oral bisphosphonates may be considered, but must be used 
with caution in patients with portal hypertension and esophageal 
varices (5). 
Recently, there has been increasing evidence that PSC recurs 
after liver transplant. The diagnosis of recurrent PSC is a chal-
lenge because biliary strictures in the allograft might also be 
caused by medications, infections, ischemia, chronic rejection, 
or bile duct anastomosis stricture. The recurrence rate of PSC 
after liver transplant is estimated to be between 5% and 37% (3). 
Median survival from time of diagnosis to death or liver trans-
plantation for patients with PSC is estimated to be between 9 
and 18 years. Patients who are asymptomatic at the time of 
diagnosis have a significantly better prognosis (3).
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Aeromedical Issues 
This case obviously presents with numerous potential 
aeromedical concerns related to his multiple diagnoses (PSC, 
ulcerative colitis, hypersplenism, thrombocytopenia), and their 
treatment. For purposes of the remainder of this discussion, we 
will focus on the primary sclerosing cholangitis. 
PSC aeromedical concerns include fatigue, pruritis, and 
abdominal discomfort, as well as progressive liver failure and the 
resulting potential for hepatic encephalopathy, gastrointestinal 
hemorrhage, and metabolic bone disease, also known as 
hepatic osteodystrophy (1,2) . PSC is frequently associated with 
inflammatory bowel disease, especially ulcerative colitis (1,2,3), 
and this condition may also cause symptoms of aeromedical 
significance. Fat soluble vitamin deficiencies may occur, and 
should be treated with replacement therapy. Patients with PSC 
are susceptible to repeated episodes of bacterial cholangitis and 
are also prone to develop pigmented biliary stones (4).  
The most worrisome complication of PSC is 
cholangiocarcinoma, which occurs in 8%-14% of patients, 
and can be very difficult to detect. PSC can recur after liver 
transplant, with an estimated recurrence rate of between 5% 
and 37% (3). 
There are several medications that have been studied in the 
past for this disorder, such as Ursodeoxycholic acid (UDCA, 
ursodiol), colchicine, tacrolimus, steroids, and methotrexate, 
but none has been proven effective in slowing the progression 
of this disorder (5,6). Should the aviator be receiving any 
medications, the potential side effects of such medications should 
be considered, and the AME should consider contacting the 
Regional Flight Surgeon or the Aerospace Medical Certification 
Division. 
Role of the AME 
Title 14 CFR Parts 67.113, 67.213, and 67.313 describe the 
general medical standards for first-, second-, and third-class 
medical certification and states that there be no other organic, 
functional, or structural disease, defect, or limitation that may 
reasonably be expected, for the maximum duration of the airman 
medical certificate applied for or held, to make the person 
unable to perform those duties or exercise those privileges (7). 
While the Guide for Aviation Medical Examiners (8) does 
not specifically mention PSC, it does describe the data needed 
for associated conditions, such as cirrhosis, liver transplant, 
ulcerative colitis, and malignancy. An airman presenting for 
medical certification with PSC should have his certificate 
deferred, and all records relating to his condition, treatment, 
and prognosis should be forwarded to the FAA to support an 
issuance of an airman medical certificate. 
Outcome 
Based on favorable consultant reports, this airman was 
granted a special issuance first-class medical certificate valid for 
6 months. It was recommended that he continue close follow-
up with his physicians to observe for evidence of liver failure, 
and should he develop any hyperbilirubinemia or evidence of 
encephalopathy that he be immediately suspended from flying. 
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NOTES
(1)   A 3½-day theme AME seminar held in conjunction with the Aerospace Medical Association (AsMA). This seminar is a Medical 
Certification theme, with aeromedical certification lectures presented by FAA medical review officers, in addition to other medical 
specialty topics. Registration must be made through AsMA at (703) 739-2240. A registration fee will be charged by AsMA to cover 
their overhead costs. Registrants have full access to the AsMA meeting. CME credit for the FAA seminar is free.
(2)  A 4½-day basic AME seminar focused on preparing physicians to be designated as aviation medical examiners. Call your Regional 
Flight Surgeon.
(3)   A 2½-day theme aviation medical examiner (AME) seminar consisting of aviation medical examiner-specific subjects plus subjects 
related to a designated theme. Registration must be made through the Oklahoma City AME Programs staff, (405) 954-4831. 
NEU= Neurology, OOE= Opthalmology-Otolaryngology-Endocrinology, CAR= Cardiology.
(4)  This seminar is being sponsored by the Civil Aviation Medical Association (CAMA) and is sanctioned by the FAA as fulfilling the 
FAA recertification training requirement. Registration will be through the CAMA Website: 
www.civilavMeD.coM.
The Civil Aerospace Medical Institute is accredited by the Accreditation Council for Continuing Medical 
Education to sponsor continuing medical education for physicians.
2013 AME Seminar Schedule
November 15–17 Sacramento, California CAR (3)
2014 AME Seminar Schedule
February 21-23 Atlanta, Georgia  NEU (3)*
March 24-28 Oklahoma City, Oklahoma Basic (2)
May 12-15 San Diego, California AsMA (1)
July 14-18 Oklahoma City, Oklahoma Basic (2)
August 8-10 Bethesda, Maryland  OOE* (3)
October 9-11 Reno, Nevada  CAMA (4)
October 27-31  Oklahoma City, Oklahoma Basic (2)
November 21-23 San Antonio, Texas  CAR (TBD)*
*SEMINAR IS TENTATIVE 
AME Basic Training Class Oct. 28-Nov. 1, 2013